Investment Thesis
Johnson & Johnson demonstrates exceptional financial health with industry-leading profitability (28.5% net margin, 34.6% operating margin) and robust cash generation ($19.7B free cash flow). The 90.6% YoY net income growth, combined with strong fundamentals (210x interest coverage, 0.51x debt/equity), reflects operational excellence and disciplined capital management in a stable pharmaceutical business.
JNJ Strengths
- Exceptional profitability: 28.5% net margin and 67.9% gross margin exceed pharmaceutical industry standards
- Outstanding cash generation: $19.7B free cash flow with 20.9% FCF margin demonstrates sustainable earnings quality
- Superior capital efficiency: 32.9% ROE and 13.5% ROA indicate excellent returns on invested capital
- Fortress balance sheet: 210x interest coverage and 0.51x debt/equity provide substantial financial flexibility
- Significant earnings growth: 90.6% YoY net income increase shows strong operational momentum
- Solid revenue growth: 6.0% YoY revenue expansion in mature pharmaceutical sector is respectable
JNJ Risks
- Tight liquidity position: 1.03x current ratio and 0.77x quick ratio suggest limited short-term flexibility
- High debt load: $41.4B long-term debt represents 50.8% of equity, though well-covered by cash flows
- Significant insider activity: 31 Form 4 filings in 90 days warrants monitoring for potential management concerns
Key Metrics to Watch
- Operating cash flow sustainability and trends relative to net income
- Current ratio and working capital dynamics to assess liquidity improvements
- Debt reduction pace and interest coverage stability
- Revenue growth acceleration in key therapeutic areas
- Free cash flow conversion and capital allocation decisions
JNJ Financial Metrics
Revenue
$94.2B
Net Income
$26.8B
EPS (Diluted)
$11.03
Free Cash Flow
$19.7B
Total Assets
$199.2B
Cash Position
$19.7B
JNJ Profitability Ratios
Gross Margin
67.9%
Operating Margin
34.6%
Net Margin
28.5%
ROE
32.9%
ROA
13.5%
FCF Margin
20.9%
JNJ Balance Sheet & Liquidity
Current Ratio
1.03x
Quick Ratio
0.77x
Debt/Equity
0.51x
Debt/Assets
59.1%
Interest Coverage
210.20x
Long-term Debt
$41.4B
Disclaimer: This analysis is generated by Claude AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: Mar 18, 2026 |
Data as of: 2025-12-28 |
Powered by Claude AI